MA25509A1 - Composition destinee au traitement de l'hepatite c - Google Patents

Composition destinee au traitement de l'hepatite c

Info

Publication number
MA25509A1
MA25509A1 MA26657A MA26657A MA25509A1 MA 25509 A1 MA25509 A1 MA 25509A1 MA 26657 A MA26657 A MA 26657A MA 26657 A MA26657 A MA 26657A MA 25509 A1 MA25509 A1 MA 25509A1
Authority
MA
Morocco
Prior art keywords
hepatitis
treatment
composition
Prior art date
Application number
MA26657A
Other languages
English (en)
French (fr)
Inventor
Wassyl Nowicky
Original Assignee
Nowicky Wassili
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nowicky Wassili filed Critical Nowicky Wassili
Publication of MA25509A1 publication Critical patent/MA25509A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA26657A 2000-03-22 2002-05-28 Composition destinee au traitement de l'hepatite c MA25509A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0048100A AT408719B (de) 2000-03-22 2000-03-22 Mittel zur behandlung von hepatitis c

Publications (1)

Publication Number Publication Date
MA25509A1 true MA25509A1 (fr) 2002-07-01

Family

ID=3674939

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26657A MA25509A1 (fr) 2000-03-22 2002-05-28 Composition destinee au traitement de l'hepatite c

Country Status (17)

Country Link
JP (1) JP2003527414A (ru)
KR (1) KR20020087045A (ru)
CN (1) CN1416347A (ru)
AT (1) AT408719B (ru)
AU (1) AU2001239000A1 (ru)
BG (1) BG107088A (ru)
BR (1) BR0107211A (ru)
CA (1) CA2389173A1 (ru)
EA (1) EA200200584A1 (ru)
HR (1) HRP20020367A2 (ru)
IL (1) IL149314A0 (ru)
IS (1) IS6360A (ru)
MA (1) MA25509A1 (ru)
MX (1) MXPA02004993A (ru)
NO (1) NO20022253L (ru)
PL (1) PL365000A1 (ru)
WO (1) WO2001070203A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695417A5 (de) * 2001-11-15 2006-05-15 Ddr Wassyl Nowicky Dipl Ing Verfahren zur Umsetzung von Alkaloiden.
EP1459753A1 (en) 2003-03-18 2004-09-22 Nowicky, Wassyl, Dipl.-Ing. DDr. Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments
WO2008039179A1 (en) * 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
CN106343303A (zh) * 2015-07-13 2017-01-25 张如安 灭杀乙肝病毒的饮料
CN106109538A (zh) * 2016-07-29 2016-11-16 桂林淮安天然保健品开发有限公司 治疗丙肝的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3128018A1 (de) * 1981-07-13 1983-04-07 Wassyl 1060 Wien Nowicky "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze"
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
US4816462A (en) * 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer

Also Published As

Publication number Publication date
NO20022253D0 (no) 2002-05-10
AU2001239000A1 (en) 2001-10-03
BR0107211A (pt) 2004-01-06
HRP20020367A2 (en) 2004-02-29
MXPA02004993A (es) 2003-10-14
CN1416347A (zh) 2003-05-07
CA2389173A1 (en) 2001-09-27
KR20020087045A (ko) 2002-11-21
IS6360A (is) 2002-04-24
EA200200584A1 (ru) 2003-06-26
NO20022253L (no) 2002-05-10
AT408719B (de) 2002-02-25
WO2001070203A2 (de) 2001-09-27
BG107088A (en) 2003-05-30
PL365000A1 (en) 2004-12-27
JP2003527414A (ja) 2003-09-16
ATA4812000A (de) 2001-07-15
WO2001070203A3 (de) 2002-09-06
IL149314A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
FR20C1039I2 (fr) Derives de l'uk-2a
LTPA2020001I1 (lt) Anti-IL-12 antikūnai, kompozicijos, būdai ir panaudojimas Krono patologijai gydyti
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
MA26207A1 (fr) Compositions de traitement de l'eau.
MA25823A1 (fr) Compositions pour le traitement de l'eau.
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
EE05158B1 (et) 1,5-bensotiasepiinid ja nende kasutamine antilipideemiliste vahenditena
NO2012018I2 (no) Canakinumab eller direkte ekvivalenter derav
DE69912223D1 (de) Methylmethacrylat-Zusammensetzung
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
PT1250321E (pt) Composicao de gliburida
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
DE60008353D1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
ID25765A (id) Komposisi pembersih kulit
FR2758465B1 (fr) Composition pour le traitement de l'amiante
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c